XRAY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
XRAY is not a good buy right now for an impatient investor looking for immediate upside. Price is sitting right at the pivot (~12.50) with weakening momentum (MACD rolling over) and options flow skewed bearish (put volume dominance). With no fresh news catalyst and the last reported quarter showing declining revenue/margins and a large net loss, the near-term risk/reward doesn’t favor buying at current levels.
Trend/momentum: Mixed-to-bearish. The MACD histogram (-0.0406) is below zero and negatively expanding, which typically signals fading upward momentum / increasing downside pressure. RSI(6) at ~50.3 is neutral, confirming a lack of strong buying pressure. Moving averages: Converging MAs suggest consolidation rather than a clean uptrend. Key levels: Pivot 12.501 (price is essentially at this level). Support: S1 12.09 then S2 11.836. Resistance: R1 12.911 then R2 13.165. From 12.50, upside is capped by ~12.91/13.17 unless momentum improves, while a breakdown below 12.09 increases odds of a quick drop toward ~11.84.
Intellectia Proprietary Trading Signals
Industry tone improving: Mizuho’s dental survey commentary became more positive, and it raised its target to $14 (Neutral).
on 2026-03-02 pre-market could reset expectations if results/guide materially improve.
Execution/visibility concerns: multiple analysts highlighted low visibility, guidance cuts, and leadership/CFO turnover concerns (noted in prior updates).
Latest quarter: 2025/Q3. Growth trend: Deteriorating. Revenue fell to $904M (-4.94% YoY). Gross margin declined to 48.78 (down ~6.28% YoY), signaling margin compression. Earnings: Net income was -$427M (worse YoY by -13.56%) and EPS was -2.14 (down -13.01% YoY). Overall read: the company is not showing an improving growth/profit trend in the latest reported quarter.
Recent rating/target trend: Mostly cautious. A wave of target cuts followed Q3 (many firms moved targets down to ~$12–$14 and reiterated Neutral/Hold/Equal Weight). Barclays initiated Underweight with a $12 target. One notable bullish outlier remains: Barrington reiterated Outperform but also cut its target (to $14) and framed XRAY as a “prove it” story requiring patience. Wall Street pros vs cons: Pros: turnaround potential, sentiment/expectations appear skeptical (room for upside if execution improves), some survey-based industry tone improving. Cons: repeated target cuts, broadly Neutral-to-Underweight stance, weak visibility, and recent financial deterioration. Influential buyers/sellers: No significant hedge fund/insider trend flagged; no recent congress trading data available.
